S4W
GALT icon

Solutions 4 Wealth’s Galectin Therapeutics GALT Stock Holding History

Solutions 4 Wealth’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Hold
25,027
– – 0.15% 55
2026
Q1 		$69.8K Sell
25,027
-350
-1% -$1.06K 0.11% 54
2025
Q4 		$106K Hold
25,377
– – 0.16% 56
2025
Q3 		$107K Sell
25,377
-10,626
-30% -$40K 0.17% 56
2025
Q2 		$76K Hold
36,003
– – 0.13% 52
2025
Q1 		$43.9K Hold
36,003
– – 0.08% 52
2024
Q4 		$46.4K Hold
36,003
– – 0.08% 51
2024
Q3 		$99K Sell
36,003
-82
-0.2% -$201 0.19% 52
2024
Q2 		$81.6K Hold
36,085
– – 0.18% 44
2024
Q1 		$86.2K Hold
36,085
– – 0.24% 39
2023
Q4 		$59.9K Buy
+36,085
New +$70K 0.2% 34

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Solutions 4 Wealth's GALT Position: Q2 2026 in Review

Solutions 4 Wealth held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 25,027 shares worth $116K. The position accounts for 0.15% of the portfolio, ranked #55.

Solutions 4 Wealth first reported a position in GALT in Q4 2023 and has held it in 11 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Solutions 4 Wealth held 25,027 shares of Galectin Therapeutics worth $116K as of Q2 2026.
  • Solutions 4 Wealth left its Galectin Therapeutics share count unchanged in Q2 2026.
  • Galectin Therapeutics made up 0.15% of Solutions 4 Wealth's portfolio in Q2 2026, its #55 holding.
  • Solutions 4 Wealth first reported a position in Galectin Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Solutions 4 Wealth's 13F filing for Q2 2026, filed 29 Jul 2026.